Price MO, et al. - This prospective, randomized clinical trial was undertaken to determine if prophylactic use of netarsudil 0.02% ophthalmic solution decreases the risk of intraocular pressure (IOP) elevation correlated with prolonged use of topical corticosteroids to prevent cornea transplant rejection. One hundred twenty patients were randomized to use netarsudil (off-label) or placebo once daily for 9 months after descemet membrane endothelial keratoplasty (DMEK), and 71 fellow eyes were registered and assigned to the opposite treatment arm. Data reported that the rate of IOP elevation was 14% with netarsudil and 21% with placebo. A statistically significant reduction in the probability of steroid-induced IOP elevation after corneal transplantation compared with placebo was not achieved with netarsudil.